Does the New FDA Pill for Teen HCM Work?
Camzyos (mavacamten), a daily pill, eased the blocked outflow from the heart in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (HCM), much as it does in adults. In the trial that got it approved, no adolescent's pumping function fell below the safety threshold. If the next conversation at your teen's HCM clinic has been about septal myectomy or alcohol ablation, the pill is now an FDA-approved alternative to raise. The approval rests on one small trial that lasted 28 weeks, so how teens do on the drug over years is still unknown.
For a long time, if a teenager with obstructive HCM stayed short of breath despite a beta-blocker, the next step was surgical. A surgeon shaved down the thickened septum, or a cardiologist induced a controlled infarction with alcohol to thin it. Both work. Both are irreversible, and both require sending a kid to a center that does enough of them to do them well. That changed on September 30, 2026, when the FDA expanded Camzyos to pediatric patients who weigh at least 30 kg. For the first time, there's an FDA-approved daily pill that unblocks the outflow tract in teens, built on the same mechanism that already works in adults.
What the drug does
HCM thickens the heart muscle. In the obstructive form, the thickened septum and a misbehaving mitral valve leaflet choke off blood as the ventricle contracts, which is where the breathlessness, chest pain, and near-fainting come from. Mavacamten quiets the sarcomere itself. It binds cardiac myosin and keeps more of it in a resting state, so the heart stops squeezing too hard. The outflow tract opens, filling pressures fall, and the heart gets to work less for the same output.
That's the mechanism. It also explains the drug's main hazard: if you dial contraction down too far, the ejection fraction drops. The whole monitoring program is built around finding that line early.
The pediatric trial
SCOUT-HCM randomized 44 symptomatic adolescents, ages 12 to under 18, to mavacamten or placebo for 28 weeks. They started with heavy outflow obstruction, averaging around 79 mm Hg with Valsalva. By week 28, the drug cut that provoked gradient by about 48 mm Hg more than placebo did. No adolescent's ejection fraction fell below 50% during the main evaluation, and side effects were similar to placebo.
This is a hemodynamic win on an echo number. It is not yet proof that teens on mavacamten feel better, exercise longer, or avoid surgery in meaningful numbers. Those were secondary outcomes in a 44-patient study, which is small by design because this disease is uncommon in kids. The hard question is how much to lean on the adult data to fill that in.
Reading across from the adult evidence
The adult evidence is substantial and consistent. In EXPLORER-HCM, 251 adults randomized to mavacamten or placebo for 30 weeks improved in how they functioned as well as in their gradient. Peak oxygen uptake rose by about 1.4 mL/kg/min more than placebo, more patients improved by at least one NYHA class, and health status on the Kansas City Cardiomyopathy Questionnaire climbed about 9 points more than placebo. In VALOR-HCM, which enrolled adults already referred for septal reduction surgery, about 84% of patients avoided the procedure or no longer met criteria for it through 128 weeks on the drug. Long-term extensions out to around 180 weeks show the gradient relief holding and the heart remodeling in the right direction, with NT-proBNP dropping and wall stress easing.
The pediatric gradient drop looks a lot like what adults get. That's the basis for expecting symptom and surgery-avoidance benefits in teens too. It's also where the uncertainty comes in: the teen data are short-term echo results from a small group, which is a reasonable bridge to the adult findings until longer pediatric trials are done.
How this stacks up against surgery
For most families, the choice is between the drug and a procedure, after beta-blockers and disopyramide have run their course.
| Option | How it works | Evidence in people under 18 | Key trade-offs |
|---|---|---|---|
| Camzyos (mavacamten) | Daily pill that quiets cardiac myosin so the heart contracts less forcefully | One small, short randomized trial (SCOUT-HCM); gradient drop like adults, pumping function preserved | Likely lifelong daily use; scheduled echoes under REMS; CYP2C19 genotype guides dose; high cost; benefits reverse if stopped |
| Surgical septal myectomy | Open-heart operation that shaves the thickened septum | Decades of experience at specialized centers, including in children | One-time procedure; durable; requires a high-volume center; usual surgical risks |
| Alcohol septal ablation | Catheter-delivered alcohol that infarcts a slice of septum | Mostly adult data; limited pediatric experience | Less invasive than myectomy; risk of heart block and pacemaker; outcomes depend on anatomy |
| Beta-blocker or disopyramide | Slow the heart and reduce contractility | Standard first-line therapy | Often inadequate once a teen is clearly symptomatic |
What the daily reality looks like
Camzyos is only dispensed through a REMS program. In practice that means a certified prescriber, enrollment paperwork, a baseline echocardiogram, and follow-up echoes on a scheduled interval to catch a falling ejection fraction before it becomes a problem. The drug is cleared by CYP2C19, so genotype guides the starting and maximum dose.
Across adult registries and extensions, roughly 4% to 11% of patients drop below 50% ejection fraction at some point; nearly all recover when the drug is paused and then resumed at a lower dose. New atrial fibrillation runs around 6% to 14% over longer follow-up. The drug can harm a developing fetus, so it isn't used in pregnancy. The wholesale price launched at about $89,500 a year, retail now runs about $9,300 to $10,200 per 30 capsules, and there's no generic. Patient-assistance programs from the manufacturer are the usual route when insurance pushes back.
Who this is for
The label is specific, and it matters. Camzyos is for a child or teen who weighs at least 30 kg, has obstructive physiology on echo, is symptomatic at NYHA class II or III, and has a baseline ejection fraction of 55% or better. The adult trial of mavacamten in nonobstructive HCM did not show symptom or exercise benefit, so this is not a drug for every thickened heart. It is a drug for the specific group where blood is being obstructed on its way out of the ventricle.
If that's your teen, this approval converts a surgical decision into a two-option conversation at a specialized HCM center. The pill isn't a one-time fix. The benefit depends on taking it, and the gradient tends to come back if the drug stops. That's a different kind of commitment than myectomy, which is one hard thing then done. Neither is obviously better in the abstract; the right answer depends on anatomy, how a family weighs a procedure against a lifelong medication, and whether CYP2C19 metabolism, drug interactions, and insurance make the pill realistic to stay on.
What would change the picture
The approval rests on a small, short trial that measured a hemodynamic surrogate. Making the pill a default choice would take a longer and larger pediatric trial, or a pooled registry, that measures what families want to know. Does a teen on mavacamten exercise more, feel better, and skip surgery at the rates adults do? What happens to growth, arrhythmias, and ejection fraction over several years of use? And when pediatric HCM guidelines next update, how will they place the pill alongside myectomy for a symptomatic 15-year-old? Until those answers come in, Camzyos is a reasonable option to discuss at a specialized HCM clinic for a teen who fits the label.


